Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 6 , Pages 510-527 , November 2006

Nucleic acid-based marker approaches to urologic cancers

References 

  1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  2. Carr KM, Rosenblatt K, Petricoin EF, et al. Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy. Hum Genomics. 2004;1:134–140
  3. Rountree MR, Bachman KE, Herman JG, et al. DNA methylation, chromatin inheritance, and cancer. Oncogene. 2001;20:3156–3165
  4. Fearon ER. Molecular genetic studies of the adenoma-carcinoma sequence. Adv Intern Med. 1994;39:123–147
  5. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1:157–162
  6. Fearon ER. A genetic basis for the multi-step pathway of colorectal tumorigenesis. Princess Takamatsu Symp. 1991;22:37–48
  7. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9:138–141
  8. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science. 2001;293:1068–1070
  9. Ehrlich M. DNA methylation in cancer: Too much, but also too little. Oncogene. 2002;21:5400–5413
  10. Holth LT, Chadee DN, Spencer VA, et al. Chromatin, nuclear matrix and the cytoskeleton: Role of cell structure in neoplastic transformation. (review) Int J Oncol. 1998;13:827–837
  11. Jain KK. Personalized medicine for cancer: From drug development into clinical practice. Expert Opin Pharmacother. 2005;6:1463–1476
  12. Hood L, Heath JR, Phelps ME, et al. Systems biology and new technologies enable predictive and preventative medicine. Science. 2004;306:640–643
  13. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30
  14. Soh S, Kattan MW, Berkman S, et al. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?. J Urol. 1997;157:2212–2218
  15. Carter HB. PSA and the natural course of prostate cancer. In:  Schröder FH editors. Recent advances in prostate cancer and BPH: The proceedings of the IV Congress on Progress and Controversies in Oncological Urology (PACIOU IV), held in Rotterdam, the Netherlands, April 1996. New York (NY): Parthenon; 1997;p. 187–195
  16. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15–36
  17. Stamey TA, Donaldson AN, Yemoto CE, et al. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes. J Urol. 1998;160:2412–2417
  18. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  19. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy (The 15-year Johns Hopkins experience). Urol Clin North Am. 2001;28:555–565
  20. Millikan R, Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology (Williston Park). 1997;11:180–193
  21. Brenner S, Johnson M, Bridgham J, et al. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat Biotechnol. 2000;18:630–634
  22. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet. 1999;21:33–37
  23. Valasek MA, Repa JJ. The power of real-time PCR. Adv Physiol Educ. 2005;29:151–159
  24. Mundle SD, Sokolova I. Clinical implications of advanced molecular cytogenetics in cancer. Expert Rev Mol Diagn. 2004;4:71–81
  25. Montironi R, Mazzucchelli R, Scarpelli M. Molecular techniques and prostate cancer diagnostic. Eur Urol. 2003;44:390–400
  26. Carpten JD, Makalowska I, Robbins CM, et al. A 6-Mb high-resolution physical and transcription map encompassing the hereditary prostate cancer 1 (HPC1) region. Genomics. 2000;64:1–14
  27. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet. 2002;30:181–184
  28. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366–381
  29. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet. 2004;1:R103–R121
  30. Casey G, Neville PJ, Plummer SJ, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet. 2002;32:581–583
  31. Nakazato H, Suzuki K, Matsui H, et al. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer. 2003;89:691–696
  32. Noonan-Wheeler FC, Wu W, Roehl KA, et al. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate. 2005;66:49–56
  33. Xu J, Zheng SL, Hawkins GA, et al. Linkage and association studies of prostate cancer susceptibility: Evidence for linkage at 8p22–23. Am J Hum Genet. 2001;69:341–350
  34. Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet. 2002;32:321–325
  35. Xu J, Zheng SL, Komiya A, et al. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet. 2003;72:208–212
  36. Rennert H, Zeigler-Johnson CM, Addya K, et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev. 2005;14:949–957
  37. DeMarzo AM, Nelson WG, Isaacs WB, et al. Pathological and molecular aspects of prostate cancer. Lancet. 2003;361:955–964
  38. Moyzis RK, Buckingham JM, Cram LS, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A. 1988;85:6622–6626
  39. Allsopp RC, Chang E, Kashefi-Aazam M, et al. Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res. 1995;220:194–200
  40. Donaldson L, Fordyce C, Gilliland F, et al. Association between outcome and telomere DNA content in prostate cancer. J Urol. 1999;162:1788–1792
  41. Fordyce CA, Heaphy CM, Joste NE, et al. Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol. 2005;173:610–614
  42. Meeker AK, Hicks JL, Iacobuzio-Donahue CA, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res. 2004;10:3317–3326
  43. Loberg RD, Fridman Y, Pienta BA, et al. Detection and isolation of circulating tumor cells in urologic cancers: A review. Neoplasia. 2004;6:302–309
  44. Shay JW, Wright WE. Telomerase activity in human cancer. Curr Opin Oncol. 1996;8:66–71
  45. Meid FH, Gygi CM, Leisinger HJ, et al. The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. J Urol. 2001;165:1802–1805
  46. Lin Y, Uemura H, Fujinami K, et al. Detection of telomerase activity in prostate needle-biopsy samples. Prostate. 1998;36:121–128
  47. Botchkina GI, Kim RH, Botchkina IL, et al. Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity. Clin Cancer Res. 2005;11:3239–3243
  48. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975–5979
  49. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695–2698
  50. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8–15
  51. Glinsky GV, Glinskii AB, Stephenson AJ, et al. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest. 2004;113:913–923
  52. Stephenson AJ, Smith A, Kattan MW, et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer. 2005;104:290–298
  53. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005;115:1503–1521
  54. Bastian PJ, Yegnasubramanian S, Palapattu GS, et al. Molecular biomarker in prostate cancer: The role of CpG island hypermethylation. Eur Urol. 2004;46:698–708
  55. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: Implication for diagnosis and treatment. J Natl Cancer Inst. 2005;97:103–115
  56. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30:445–600
  57. Lee WH, Isaacs WB, Bova GS, et al. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: A new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev. 1997;6:443–450
  58. Harden SV, Sanderson H, Goodman SN, et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst. 2003;95:1634–1637
  59. Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res. 2005;11:4037–4043
  60. Hoque MO, Topaloglu O, Begum S, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 2005;23:6569–6575
  61. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004;64:1975–1986
  62. Jones PA, Droller MJ. Pathways of development and progression in bladder cancer: New correlations between clinical observations and molecular mechanisms. Semin Urol. 1993;11:177–192
  63. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994;54:784–788
  64. van Tilborg AA, de Vries A, de Bont M, et al. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet. 2000;9:2973–2980
  65. Brandau S, Bohle A. Bladder cancer (I. Molecular and genetic basis of carcinogenesis). Eur Urol. 2001;39:491–497
  66. Duggan BJ, Gray SB, McKnight JJ, et al. Oligoclonality in bladder cancer: The implication for molecular therapies. J Urol. 2004;171:419–425
  67. Paiss T, Wohr G, Hautmann RE, et al. Some tumors of the bladder are polyclonal in origin. J Urol. 2002;167:718–723
  68. Hafner C, Knuechel R, Zanardo L, et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene. 2001;20:4910–4915
  69. Louhelainen J, Wijkstrom H, Hemminki K. Allelic losses demonstrate monoclonality of multifocal bladder tumors. Int J Cancer. 2000;87:522–527
  70. Vriesema JL, Aben KK, Witjes JA, et al. Superficial and metachronous invasive bladder carcinomas are clonally related. Int J Cancer. 2001;93:699–702
  71. Sokolova IA, Halling KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000;2:116–123
  72. Bubendorf L, Grilli B, Sauter G, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 2001;116:79–86
  73. Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol. 2002;168:1950
  74. Lee DH, Yang SC, Hong SJ, et al. Telomerase: A potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res. 1998;4:535–538
  75. Ito H, Kyo S, Kanaya T, et al. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin Cancer Res. 1998;4:2807–2810
  76. Eissa S, Labib RA, Mourad MS, et al. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer. Eur Urol. 2003;44:687–694
  77. Weikert S, Krause H, Wolff I, et al. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int J Cancer. 2005;117:274–280
  78. Sanchini MA, Gunelli R, Nanni O, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA. 2005;294:2052–2056
  79. Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA. 2001;285:324–328
  80. Weikert S, Christoph F, Schrader M, et al. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer. 2005;116:100–104
  81. Wang H, Xi X, Kong X, et al. The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol. 2004;130:487–490
  82. Mao L, Schoenberg MP, Scicchitano M, et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science. 1996;271:659–662
  83. van Rhijn BW, Lurkin I, Kirkels WJ, et al. Microsatellite analysis–DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: A phase II trial. Cancer. 2001;92:768–775
  84. Vaish M, Mandhani A, Mittal RD, et al. Microsatellite instability as prognostic marker in bladder tumors: A clinical significance. BMC Urol. 2005;5:2–9
  85. Migaldi M, Sartori G, Rossi G, et al. Prevalence and prognostic significance of microsatellite alterations in young patients with bladder cancer. Mod Pathol. 2005;18:1176–1186
  86. Lee MG, Kim HY, Byun DS, et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res. 2001;61:6688–6692
  87. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001;61:8659–8663
  88. Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23:2903–2910
  89. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002;8:464–470
  90. Dulaimi E, Uzzo RG, Greenberg RE, et al. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res. 2004;10:1887–1893
  91. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet. 2003;33:90–96
  92. Dyrskjot L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res. 2005;11:4029–4036
  93. de la Taille A, Buttyan R, Katz AE, et al. Biomarkers of renal cell carcinoma (Past and future considerations). Urol Oncol. 2000;5:139–148
  94. Lam JS, Shvarts O, Leppert JT, et al. Renal cell carcinoma 2005: New frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005;173:1853–1862
  95. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163–2172
  96. Heidenreich A, Schrader AJ, Varga Z. Basic science and research in renal cell carcinoma: From workbench to bedside. Curr Opin Urol. 2003;13:457–462
  97. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 1998;12:417–423
  98. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865–875
  99. Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst. 2002;94:1569–1575
  100. Velickovic M, Delahunt B, Storkel S, et al. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance. Cancer Res. 2001;61:4815–4819
  101. Brauch H, Weirich G, Brieger J, et al. VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 2000;60:1942–1948
  102. Schraml P, Struckmann K, Hatz F, et al. VHL mutations and their correlation with tumor cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol. 2002;196:186–193
  103. Kim JH, Jung CW, Cho YH, et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep. 2005;13:859–863
  104. Kondo K, Yao M, Yoshida M, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer. 2002;34:58–68
  105. Ashida S, Furihata M, Tanimura M, et al. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: Potential biomarkers for early diagnosis and postoperative metastatic status. J Urol. 2003;169:2089–2093
  106. Alimov A, Sundelin B, Wang N, et al. Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival. Int J Oncol. 2004;25:179–185
  107. Opavsky R, Pastorekova S, Zelnik V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: Structure and exon to protein domain relationships. Genomics. 1996;33:480–487
  108. McKiernan JM, Buttyan R, Bander NH, et al. Expression of the tumor-associated gene MN: A potential biomarker for human renal cell carcinoma. Cancer Res. 1997;57:2362–2365
  109. Murakami Y, Kanda K, Tsuji M, et al. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int. 1999;83:743–747
  110. McKiernan JM, Buttyan R, Bander NH, et al. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer. 1999;86:492–497
  111. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer. 1999;81:741–746
  112. de la Taille A, Katz A, Cao Y, et al. Blood-based RT-PCR assays of MN/CA9 or PSMA: Clinical application in renal cancer patients. Urology. 2000;56:393–398
  113. Gilbert SM, Mansukhani M, Benson MC, et al. MN/CA9 expression predicts disease free survival in renal cell carcinoma. Proc Am Soc Clin Oncol. 2003;22:418;[abstract]
  114. Li G, Cuilleron M, Gentil-Perret A, et al. Rapid and sensitive detection of messenger RNA expression for molecular differential diagnosis of renal cell carcinoma. Clin Cancer Res. 2003;9:6441–6446
  115. Paul R, Ewing CM, Robinson JC, et al. Cadherin-6, a cell adhesion molecule specifically expressed in the proximal renal tubule and renal cell carcinoma. Cancer Res. 1997;57:2741–2748
  116. Shimazui T, Yoshikawa K, Uemura H, et al. Detection of cadherin-6 mRNA by nested RT-PCR as a potential marker for circulating cancer cells in renal cell carcinoma. Int J Oncol. 2003;23:1049–1054
  117. Shimazui T, Yoshikawa K, Uemura H, et al. The level of cadherin-6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma. Cancer. 2004;101:963–968
  118. Li G, Passebosc-Faure K, Gentil-Perret A, et al. Cadherin-6 gene expression in conventional renal cell carcinoma: A useful marker to detect circulating tumor cells. Anticancer Res. 2005;25:377–381
  119. Breault JE, Shiina H, Igawa M, et al. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res. 2005;11:557–564
  120. Orlando C, Gelmini S, Selli C, et al. Telomerase in urological malignancy. J Urol. 2001;166:666–673
  121. Yoshida K, Sakamoto S, Sumi S, et al. Telomerase activity in renal cell carcinoma. Cancer. 1998;83:760–766
  122. Mekhail TM, Kawanishi-Tabata R, Tubbs R, et al. Renal cell carcinoma (RCC) and telomerase activity: Relationship to stage. Urol Oncol. 2003;21:424–430
  123. Segawa N, Gohji K, Azuma H, et al. Telomerase activity in renal cell carcinoma by modified telomeric repeat amplification protocol assay. Int J Urol. 2003;10:153–159
  124. Battagli C, Uzzo RG, Dulaimi E, et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res. 2003;63:8695–8699
  125. Cairns P. Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Ann N Y Acad Sci. 2004;1022:40–43
  126. Dulaimi E, Ibanez de Caceres I, Uzzo RG, et al. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res. 2004;10:3972–3979
  127. Hoque MO, Begum S, Topaloglu O, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004;64:5511–5517
  128. Gonzalgo ML, Eisenberger CF, Lee SM, et al. Prognostic significance of preoperative molecular serum analysis in renal cancer. Clin Cancer Res. 2002;8:1878–1881
  129. von Knobloch R, Hegele A, Brandt H, et al. High frequency of serum DNA alterations in renal cell carcinoma detected by fluorescent microsatellite analysis. Int J Cancer. 2002;98:889–894
  130. Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification. Proc Natl Acad Sci USA. 2001;98:9754–9759
  131. Vasselli JR, Shih JH, Iyengar SR, et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA. 2003;100:6958–6963
  132. Sultmann H, von Heydebreck A, Huber W, et al. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res. 2005;11:646–655
  133. Moch H, Presti JC, Sauter G, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res. 1996;56:27–30
  134. Mostofi FK. Proceedings: Testicular tumors (Epidemiologic, etiologic, and pathologic features). Cancer. 1973;32:1186–1201
  135. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol. 1990;8:1777–1781
  136. Gori S, Porrozzi S, Roila F, et al. Germ cell tumors of the testis. Crit Rev Oncol Hematol. 2005;53:141–164
  137. Fleming I, Cooper JS, Henson DE, et al. AJCC cancer staging manual. 5th ed.. Philadelphia (PA): Lippincott-Raven; 1998;
  138. Bosl GJ, Dmitrovsky E, Reuter VE, et al. Isochromosome of the short arm of chromosome 12: Clinically useful markers for male germ cell tumors. J Natl Cancer Inst. 1989;81:1874–1878
  139. Heidenreich A, Srivastava S, Moul JW, et al. Molecular genetic parameters in pathogenesis and prognosis of testicular germ cell tumors. Eur Urol. 2000;37:121–135
  140. Roelofs H, Mostert MC, Pompe K, et al. Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am J Pathol. 2000;157:1155–1166
  141. Bosl GJ, Ilson DH, Rodriguez E, et al. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst. 1994;86:349–355
  142. Meng FJ, Zhou Y, Giwercman A, et al. Fluorescence in situ hybridization analysis of chromosome 12 anomalies in semen cells from patients with carcinoma in situ of the testis. J Pathol. 1998;186:235–239
  143. Looijenga LH, Oosterhuis JW. Clinical value of the X chromosome in testicular germ-cell tumours. Lancet. 2004;363:6–8
  144. Kawakami T, Okamoto K, Ogawa O, et al. XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet. 2004;363:40–42
  145. Hautkappe AL, Lu M, Mueller H, et al. Detection of germ-cell tumor cells in the peripheral blood by nested reverse transcription-polymerase chain reaction for alpha-fetoprotein-messenger RNA and beta human chorionic gonadotropin-messenger RNA. Cancer Res. 2000;60:3170–3174
  146. Jensen M, Leffers H, Petersen JH, et al. Frequent polymorphism of the mitochondrial DNA polymerase gamma gene (POLG) in patients with normal spermiograms and unexplained subfertility. Hum Reprod. 2004;19:65–70
  147. Nowak R, Zub R, Skoneczna I, et al. CAG repeat polymorphism in the DNA polymerase gamma gene in a Polish population: An association with testicular cancer risk. Ann Oncol. 2005;16:1211–1212
  148. Mayer F, Gillis AJ, Dinjens W, et al. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res. 2002;62:2758–2760
  149. Velasco A, Riquelme E, Schultz M, et al. Microsatellite instability and loss of heterozygosity have distinct prognostic value for testicular germ cell tumor recurrence. Cancer Biol Ther. 2004;3:1152–1158
  150. Koul S, McKiernan JM, Narayan G, et al. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer. 2004;3:16–28
  151. Rao PH, Houldsworth J, Palanisamy N, et al. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res. 1998;58:4260–4263
  152. Sugimura J, Foster RS, Cummings OW, et al. Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. Clin Cancer Res. 2004;10:2368–2378

PII: S1078-1439(06)00146-3

doi: 10.1016/j.urolonc.2006.07.002

Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 6 , Pages 510-527 , November 2006

Article Tools